UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549  FORM
10-Q  (Mark One)  [X] QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly
period ended June 30, 2010  [
 ] TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition
period from ____ to ____  Commission File No.
333-144226  ARTVENTIVE MEDICAL GROUP, INC. (Exact
name of registrant as specified in its charter)  Nevada 26-0148468 (State
or other jurisdiction (IRS
Employer of
incorporation or organization) Identification
No.)  1797 Playa Vista, San Marcos, California, 92078 (Address
of principal executive offices)  (760) 471-7700 (Registrants telephone number)   Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes  [x]  No  [  ]  Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes [  ] No [ X ] Not Required  Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company.  See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange
Act.  Large accelerated filer [  ] Accelerated filer [  ] Non-accelerated filer [  ] Smaller reporting company [ X ]  Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).  Yes [  ]  No
[x]    State the number of shares outstanding of each of the issuers
classes of common equity, as of the latest practicable date:  As of
July 12, 2010, there were 46,814,117 shares of the Companys common stock issued
and outstanding.   PART I  FINANCIAL INFORMATION  Item 1.
 Financial Statements.          ArtVentive Medical Group Inc. Financial Statements (Unaudited) For
the Period from January 23, 2007 (Inception) to June 30, 2010                   Balance
Sheets as of June 30, 2010 (unaudited) and December 31, 2009 Statement
1  Statements of
Operations and Comprehensive Loss (unaudited) for the three and six month
periods ended June 30, 2010
and June 30, 2009; and
the period from January 23, 2007 (Inception) through June 30, 2010 Statement
2  Statements of Cash
Flows (unaudited) for the six month periods ended June 30, 2010 and June 30,
 2009; and
for the period from January 23, 2007 (Inception) to June 30, 2010 Statement
3   Notes to Financial
Statements (unaudited)   Statement 1 ArtVentive Medical
Group Inc. A Development
Stage Company Balance Sheets June 30, 2010 and
December 31, 2009   ASSETS
June 30,2010
(unaudited)
December 31,
2009CURRENTCash
and cash equivalents
Payroll
prefunding-NPC
Prepaid
insurance
$
762,339
6,625
548
$
60,791
-
-TOTAL
CURRENT ASSETS
769,512
60,791PROPERTY,
PLANT AND EQUIPMENTOFFICE
EQUIPMENT
1,382
-ACCUMULATED
DEPRECIATION
(92)
-NET
PROPERTY, PLANT AND EQUIPMENT
1,290
-TOTAL
ASSETS
$
770,802
$
60,791LIABILITIES
AND STOCKHOLDERS EQUITY (DEFICIT)CURRENTAccounts
payable
$
43,496
$
4,411Payroll
taxes payable
490
-Convertible
note payable (Note 5)
-
150,000TOTAL
LIABILITIES
43,986
154,411STOCKHOLDERS
EQUITY (DEFICIT)Common
stock, par value $.001, 100,000,000 sharesauthorized,
46,814,117 and 21,430,200 shares issued and outstanding as of June 30,
2010 and December 31, 2009 respectively  after giving effect to 1.65
for 1 split on February 12, 2010
46,814
21,430Additional
paid in capital
1,332,089
89,473Deficit
accumulated during the development stage
(652,087)
(204,523)TOTAL
STOCKHOLDERS EQUITY (DEFICIT)
726,816
(93,620)TOTAL
LIABILITIES AND STOCKHOLDERS
EQUITY
(DEFICIT)
$
770,802
$
60,791  (See
accompanying notes)


Statement 2 ArtVentive Medical
Group Inc. A Development
Stage Company Statements
of Operations and Comprehensive Loss (Unaudited)  For the three months ended June 30, 2010
For the three months ended
June 30, 2009
For the six months ended June 30, 2010
For the six months ended June 30, 2009
For the period from January 23, 2007 (Inception) to June
30, 2010REVENUES
$
NIL
$
NIL
$
           NIL
$
            NIL
$
NILOPERATING
EXPENSESExploration
costs
-
-
-
-
45,533Research
and development
284,006
-
294,006
-
294,006Selling,
general and administrative
97,577
3,909
155,837
14,084
314,311Depreciation
expense
92
-
92
-
608OPERATING
LOSS BEFORE OTHER ITEMS AND INCOME TAX
(381,675)
(3,909)
(449,935)
(14,084)
(654,458)OTHER
INCOME/(EXPENSE)INTEREST
INCOME
1,589
-
2,371
-
2,371Foreign
currency translation adjustment
-
-
-
(380)
-Income
tax (expense) benefit
-
-


-NET
LOSS AVAILABLE TO COMMON STOCKHOLDERS
(380,086)
(3,909)
(447,564)
(14,464)
(652,087)COMPREHENSIVE
LOSS FOR THE PERIOD
$
(380,086)
$
(3,909)
$      (447,564)
$     (14,464)
$   (652,087)BASIC
AND DILUTED LOSS PER COMMON SHARE
(0.00)
(0.00)
(0.00)
(0.00)WEIGHTED
AVERAGE SHARES OUTSTANDING
46,810,601
12,988,000
44,768,551
12,988,000


(See
accompanying notes)


Statement 3 ArtVentive Medical
Group Inc. A Development
Stage Company Statements
of Cash Flows (Unaudited)  For the six months ended June 30, 2010
For the six months ended June 30, 2009
For the period  from January
23, 2007 (Inception) to
June 30, 2010CASH
FLOW FROM OPERATING ACTIVITIESNet
loss
$
(447,564)
$
(14,084)
$ (652,087)ADJUSTMENTS
TO RECONCILE NET LOSS TO NET CASH USED BY OPERATING ACTIVITIESNon-cash
expenses
-
-
60,805Depreciation
expense
92
-
608Issuance
of common stock for services
18,000

18,000CHANGES
IN OPERATING ASSETS AND LIABILITIES
Payroll
prefunding-NPC
(6,625)
-
(6,625)Prepaid
Insurance
(548)
-
(548)Accounts
payable
39,085
(6,805)
43,496Payroll
taxes payable
490
-
490Accounts
payable  related party
-
-
39,000NET
CASH USED BY OPERATING ACTIVITIES
(397,070)
(20,889)
(496,861)CASH
FLOWS FROM INVESTING ACTIVITIESDisposal
of equipment
-
-
745Purchase
of equipment
(1,382)

(2,625)NET
CASH USED BY INVESTING ACTIVITIES
(1,382)
-
(1,880)CASH
FLOWS FROM FINANCING ACTIVITIESIssuance
of common stock for cash
1,100,000
-
1,111,080Convertible
note payable (see Note 4)
-
-
150,000NET
CASH PROVIDED BY FINANCING ACTIVITIES
1,100,000
-
1,261,080NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
701,548
(20,889)
762,339Effect of
exchange rate changes on cash
-
(380)
-CASH,
BEGINNING OF PERIOD
60,791
93,139
-CASH,
END OF PERIOD
$
762,339
$
71,870
$ 762,339NON-CASH
INVESTING AND FINANCING ACTIVITIESSTOCK
ISSUED UPON CONVERSION OF NOTE PAYABLE
$
-
$
-
$ 150,000FORGIVENESS
OF RELATED PARTY NOTE; APPLIED TO PAID IN CAPITAL
$
-
$
39,000
$ 39,000SHARES
ISSUED FOR NET ASSETS OF ARTVENTIVE
$
         21,430
$
                  -
$
                  -   (See
accompanying notes)    ArtVentive Medical
Group Inc. A Development
Stage Company Notes to Financial
Statements (Unaudited) June 30,
2010  1. BASIS OF FINANCIAL STATEMENT PRESENTATION  The accompanying unaudited condensed financial statements have
been prepared by the Company pursuant to the rules and regulations of the
Securities and Exchange Commission.  Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with U.S. generally accepted accounting principles have been condensed or
omitted in accordance with such rules and regulations.  The information
furnished in the interim condensed financial statements includes normal
recurring adjustments and reflects all adjustments, which, in the opinion of
management, are necessary for a fair presentation of such financial statements.
 Although management believes the disclosures and information presented are
adequate to make the information not misleading, it is suggested that these
interim condensed financial statements be read in conjunction with the Company's
audited financial statements and notes thereto included in its Form 10-K filed
on March 31, 2010.  Operating results for the six months ended June 30,
2010 are not necessarily indicative of the results to be expected for the fiscal
year ended December 31, 2010.  2. ORGANIZATION The company was originally incorporated under the name of Big Bear
Resources Inc. a USA Company registered in the State of Nevada on January 23,
2007.   The Company changed its name to Uranium Plus Resources Inc. on
March 21, 2008.  Following the acquisition of the business of ArtVentive
Inc. the Company changed its name on January 26, 2010, from Uranium Plus
Resources Inc. to ArtVentive Medical Group, Inc.  The Company is a medical device corporation, focused on
developing, manufacturing and marketing a family of Endoluminal Occlusion
Devices (EOS).  Through its innovative, proprietary technology the Company
has developed unique minimally invasive occlusion devices and procedures,
bringing the current interventional, image guided techniques to a new level of
sophistication, potentially resolving significant and unaddressed health issues.
The EOS device being developed by the Company targets a substantive market
demand in several major clinical areas, including women's health, peripheral and
neurological vascular disorders, and interventional cardiology procedures.  To date, the Companys activities have been limited to its
formation, development of EOS, intellectual property continuous development and
patent filing, generation of regulatory strategy for initial clinical
indications for FDA and European submissions and approval, corporate operations
and the raising of equity capital.  3. SIGNIFICANT
ACCOUNTING POLICIES USE
OF ESTIMATES  The preparation of the Companys financial statements in
conformity with accounting principles generally accepted in the United States
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amount of
revenues and expenses during the reporting period.  Actual results could
differ from those estimates.  The Companys periodic filings with the
Securities and Exchange Commission include, where applicable, disclosures of
estimates,      ArtVentive Medical
Group Inc. A Development
Stage Company Notes to Financial
Statements (Unaudited) June 30,
2010  assumptions,
uncertainties and markets that could affect the financial statements and future
operations of the Company.  FOREIGN CURRENCY
TRANSLATIONS The Companys functional and reporting currency is the US dollar.
 All transactions initiated in other currencies are translated into US
dollars using the exchange rate prevailing on the date of transaction.
 Monetary assets and liabilities denominated in foreign currencies are
translated into the US dollar at the rate of exchange in effect at the balance
sheet date.  Unrealized exchange gains and losses arising from such
transactions are deferred until realization and are included as a separate
component of stockholders equity (deficit) as a component of other
comprehensive income or loss. Upon realization, the amount deferred is
recognized in income in the period when it is realized.  The Company recorded an unrealized foreign currency translation
gain, totaling $0 for the period from January 23, 2007 (Inception) to June 30,
2010, in accumulated other comprehensive income.  Cash and cash equivalents consist of funds on deposit with banks.
 The Company has no cash equivalents.  The Company had funds on
deposit of $762,339 as at June 30, 2010.  4. CONVERTIBLE NOTE PAYABLE The
Company borrowed $150,000 pursuant to an agreement dated April 29, 2008.
 The loan was payable on demand by the Lender.  The Lender had the
option to convert the loan into common shares of the Company at a rate of 1
common share for each $1 borrowed (150,000 common shares).  In the event that repayment was demanded and the Company
defaulted, interest at a rate of 8% per annum would have been charged from the
date of demand.  All funds were in US dollars.  The note was converted into
166,666 shares at a deemed value per share of $.90 effective February 22,
2010.  5. SHARE CAPITAL Effective
April 22, 2008, the Company forward-split its issued capital stock on a ratio of
5.8 shares for each one old share.  As a result of this transaction,
11,078,000 shares were issued. Effective February 12, 2010, the Company
forward-split its issued capital stock on a ratio of 1.65 shares for each old
share. As a result of this transaction 8,442,200 shares were issued. Effective
February 19, 2010 3,767,051 shares were issued in private placement.
Consideration for the issue of additional shares has been charged against
additional paid in capital.  The adjustment has been reflected
retroactively. Effective
April 16, 2010 the Board of Directors of the Company authorized issuance of
20,000 shares to the members of its Scientific Board at a deemed value per share
of $.90.          ArtVentive Medical
Group Inc. A Development
Stage Company Notes to Financial
Statements (Unaudited) June 30,
2010  6. GOING CONCERN AND LIQUIDITY CONSIDERATIONS The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the
normal course of business.  As of June 30, 2010, the Company has a working
capital balance of $725,526 and an accumulated deficit of $652,087  In response to these challenges, management intends to raise
additional funds through public or private placement offerings.  The accompanying financial statements do not include any
adjustments that might result from the outcome of this uncertainty.  7. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In June 2009, the FASB established the Accounting Standards
Codification (Codification or ASC) as the source of authoritative accounting
principles recognized by the FASB to be applied by nongovernmental entities in
the preparation of financial statements in accordance with generally accepted
accounting principles in the United States (GAAP).  Rules and
interpretive releases of the Securities and Exchange Commission (SEC) issued
under authority of federal securities laws are also sources of GAAP for SEC
registrants.  Existing GAAP was not intended to be changed as a result of
the Codification, and accordingly the change did not impact our financial
statements.  The ASC does change the way the guidance is organized and
presented.  Statement of Financial Accounting Standards (SFAS) SFAS No. 166
(ASC Topic 810), Accounting for Transfers of Financial Assetsan Amendment of
FASB Statement No. 140, SFAS No. 167 (ASC Topic 810), Amendments to FASB
Interpretation No. 46(R), and SFAS No. 168 (ASC Topic 105), The FASB
Accounting Standards Codification and the Hierarchy of Generally Accepted
Accounting Principlesa replacement of FASB Statement No. 162 were recently
issued.  SFAS No. 166, 167, and 168 have no current applicability to the
Company or their effect on the financial statements would not have been
significant.  Accounting Standards Update (ASU) ASU No. 2009-05 (ASC Topic
820), which amends Fair Value Measurements and Disclosures  Overall, ASU No.
2009-13 (ASC Topic 605), Multiple-Deliverable Revenue Arrangements, ASU No.
2009-14 (ASC Topic 985), Certain Revenue Arrangements that include Software
Elements, and various other ASUs No. 2009-2 through ASU No. 2010-20 which
contain technical corrections to existing guidance or affect guidance to
specialized industries or entities were recently issued.  These updates
have no current applicability to the Company or their effect on the financial
statements would not have been significant.      ArtVentive Medical
Group Inc. Notes to Financial
Statements (Unaudited) June 30,
2010  8. PROVISION FOR INCOME TAXES The company recognizes the tax effects of transactions in the year
in which such transactions enter into the determination of net income,
regardless of when reported for tax purposes.  Deferred taxes are provided
in the financial statements under ASC Topic 740 to give effect to the resulting
temporary differences which may arise from differences in the bases of fixed
assets, depreciation methods, allowances, and start-up costs based on the income
taxes expected to be payable in future years. Minimal exploration stage deferred
tax assets arising as a result of net operating loss carry forwards have been
offset completely by a valuation allowance due to the uncertainty of their
utilization in future periods.  The Company adopted the provisions of ASC
Topic 740 Accounting for Uncertainty in Income Taxes, on January 1, 2007.
 As a result of the implementation of ASC 740, the Company recognized no
increase in the liability for unrecognized tax benefits. The Company has no tax positions at June 30, 2010 or December 31,
2009 for which the ultimate deductibility is highly certain but for which there
is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized
tax benefits in interest expense and penalties in operating expenses.
 During the six months ended June 30, 2010 and the year ended December 31,
2009, the Company recognized no interest and penalties.  The Company had no
accruals for interest and penalties at June 30, 2010 and December 31, 2009.  9. CONTRACTUAL OBLIGATIONS Effective February 27, 2010 the Company has entered into
employment agreements for a Chief executive Officer (CEO) and Chairman of the
Board.  The CEO agreement is for a five year term commencing March 1, 2010
at a base salary of $120,000 per annum.  The agreement includes other
employment benefits.  The Chairman is engaged under a consulting agreement
with a base fee of $100,000 per annum. 10. PURCHASE
AGREEMENT On January 8, 2010 the Company entered into an asset purchase
agreement with Artventive, Inc. a privately held company.  The Company
purchased substantially all of the assets of Artventive, Inc. which consisted
entirely of patents.  The patents were accounted for under SAB Topic 5G
using the historical cost basis of zero.  The combination was accounted for
under ASC 805 as a business combination.  Pro Forma financial information
as if the combination had taken place as of the earliest period presented has
not been included as it is not significant.  11. SUBSEQUENT EVENTS Company implemented a new ASU 2010-09. This standard
establishes general standards of accounting for and disclosure of events that
occur after the balance sheet date but before financial statements are issued.
The adoption of this accounting pronouncement did not impact our financial
position or results of operations. The Company evaluated all events or
transactions that occurred after June 30, 2010 up through the date these
financial statements were issued.


Item
2.  Managements Discussion and Analysis of Financial Condition and Results
of Operations  ArtVentive Medical Group, Inc. (AVTD or the Company), is a
Nevada Corporation trading on the OTC-BB (symbol AVTD).  On March 21, 2008,
the Company changed its name from Big Bear Resources Inc. to Uranium Plus
Resource Corporation and subsequently on January 26, 2010 the Company changed
its name to ArtVentive Medical Group, Inc.  Prior
to January 26, 2010, the Company had focused in the mining and exploration
business in  Peru.  On January 9, 2010, the Company completed the
acquisition of all of the assets of ArtVentive Medical Inc., a California
company.  The
Company is concentrating on developing, manufacturing and marketing a family of
Endoluminal Occlusion devices (EOS).  The Company, through its proprietary
technology has developed minimally invasive occlusion devices and procedures,
bringing the current interventional, image guided techniques to a new level of
sophistication, resolving potentially significant and unaddressed health issues.
 The EOS device is being developed by the Company to target market demand
in several major clinical areas, including women's health, peripheral and
neurological vascular disorders and interventional cardiology procedures.  The
Company has contracted, and expects to continue contracting with specific
American and European corporations and consulting groups to assist in the
implementation of an ongoing strategic plan for the successful international
launch, market development, commercialization and manufacturing of the Companys
products.  The Company has entered into an agreement with the Chicago,
Illinois based Medical Murray Inc., a leader in the field of medical device
development and manufacturing.  Medical Murray Inc. is recognized as being
ISO certified and FDA registered.  Also
the Company has entered in to an agreement with the Northwest Clinical Research
Group, Inc. (NCRG), located in Seattle, Washington.  NCRG has played an
intricate role in building the complex infrastructure and support necessary for
outlining the regulatory and clinical strategy, in addition to providing a
platform of quality controls parallel and synergistic to what Medical Murray is
providing.  Their responsibility also extends to encompass communication
with the FDA and European Notified Body (FDA counterpart).  The
Company has implemented its Quality Management System (QMS), based on the
requirements of, and is intended to comply with, the following regulations and
international standards: · US
FDA Quality System Regulation, 21 CFR 820 · EU
Medical Device Directive (MDD), EEC 93/42 · Canada
Medical Devices Regulations (CMDR), SOR/98-282





· ISO
13485:2003 Medical Devices  Quality Management Systems - Requirements
Regulatory Purposes Document Control System and Design History File for the EOS
project are in continuous process of implementation.  The highly secured
system utilizes Egnyte software and is hosted on the Northwest Clinical Research
Groups server.  The
Company is focused on the continued development and implementation of its
proprietary line of lumen occlusion devices in defining new opportunity within
the medical device arena.  A second patent of the Companys intellectual
property was filed with the US patent office on June 30, 2010.  To
date, the Companys activities have been limited to its formation, corporate
operations, the development of the EOS device design and testing, implementation
of quality controls and protocols, Regulatory Strategy for FDA and European
trials, raising of equity capital and executing the business of the Company as
laid out in the Business Plan of the Company.  For the
six months ended June 30, 2010, the Company incurred continuing selling, general
and administrative costs of $155,837 and research and development costs of
$294,006.  Costs for the same period in 2009 were $14,084 and $0,
respectively.  The increase in expenses was due to work on the development
of its proprietary medical device.  Item
3. Quantitative and Qualitative Disclosure about Market Risk  Not
required by smaller reporting companies.  Item 4T.
 Controls and Procedures  As of
the end of the period covered by this report, AVTD carried out an evaluation of
the effectiveness of the Companys disclosure controls and procedures (as
defined by Rule 13-15(f) and 15d-15(f) under the Securities Exchange Act of
1934) under the supervision and with the participation of ArtVentive Medical
Groups President and Principal Financial Officer.  Based on and as of the
date of such evaluation, the aforementioned officers have concluded that
ArtVentive Groups disclosure controls and procedures were not effective in
recording, processing, summarizing and reporting, on a timely basis, information
required to be disclosed by us in the reports that we file or submit under the
Exchange Act.  AVTD
also maintains a system of internal accounting controls that is designed to
provide assurance that assets are safeguarded and that transactions are executed
in accordance with managements authorization and properly recorded.  This
system is continually reviewed and is augmented by written policies and
procedures, the careful selection and training of qualified personnel and an
internal audit program to monitor its effectiveness.  There
were no significant changes in AVTDs internal controls or in other factors that
could significantly affect these controls during the second quarter ended June
30, 2010.  There were no significant deficiencies or material weaknesses,
and therefore there were no corrective actions





taken.  It should be noted that any system of controls,
however well designed and operated, can provide only reasonable, and not
absolute, assurance that the objectives of the system are met.  In
addition, the design of any control system is based in part upon certain
assumptions about the likelihood of future events.  Because of these and
other inherent limitations of control systems, there can be no assurance that
any design will succeed in achieving its stated goals under all potential future
conditions, regardless of how remote.  PART
II  INFORMATION  Item
1.  Legal Proceedings  None  Item
2.  Unregistered Sales of Equity Securities and Use of Proceeds   Item
3.  Defaults Upon Senior Securities  None  Item
4.  (Removed and Reserved)   Item
5.  Other Information  None  Item 6.
 Exhibits  Exhibit No.
Document
Location31
Rule
13a-41(a)/15d-14(a) Certifications
Included32
Section
1350 Certifications
Included





SIGNATURES  In accordance with
the requirements of the Exchange Act, the registrant caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.  ARTVENTIVE MEDICAL
GROUP, INC.  August 6, 2010   /s/ Leon
Rudakov Dr. Leon Rudakov Chief Executive
Officer, Chief Technology Officer   /s/ H. James
Graham H. James Graham President, Chief
Financial Officer